A US ban on Chinese biotech and clinical trial collaborations would return global pharmaceutical leadership to European pharmas and investors, slow American patient access to new medicines, and accelerate the US dependency that protectionism claims to prevent.

Thanks to the selfless efforts of a handful of smart and dedicated volunteers from a few tech transfer offices (TTOs), law firms, and investment firms, the fraught process by which technology licenses are extricated from universities is getting a significant upgrade.